NEWS

2025

07/07/2025

GSK completes acquisition of efimosfermin, a potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)

05/14/2025

GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)

04/28/2025

Boston Pharmaceuticals to Present the Effect of Efimosfermin Alfa on Collagen Biomarkers in Patients with F2 and F3 MASH at EASL Congress 2025

04/23/2025

Boston Pharmaceuticals to Present State-of-the-Art Lecture and Poster for Once-monthly Efimosfermin Alfa at Digestive Disease Week® 2025

2024

11/15/2024

Boston Pharmaceuticals to Announce Positive Phase 2 Data on Efimosfermin Alfa (BOS-580) in F2/F3 MASH During Late-Breaking Oral Presentation at AASLD 2024, The Liver Meeting®

10/16/2024

Boston Pharmaceuticals to Present Phase 2 Biopsy Results for Long-Acting, Once-Monthly FGF21 Analogue Efimosfermin Alfa (BOS-580) in F2 and F3 MASH in Late-Breaking Oral Presentation at AASLD, The Liver Meeting® 2024

06/06/2024

Boston Pharmaceuticals Appoints Dr. Margaret Koziel as New Chief Medical Officer

06/05/2024

Boston Pharmaceuticals Presents Data at EASL Congress 2024 Showing Treatment With Long-acting FGF21 Analogue, BOS-580, Improved Lipid Profiles in Patients with Phenotypic MASH

05/23/2024

Boston Pharmaceuticals Announces Former NIH Director, Dr. Elias Zerhouni, As the New Chair of Its Board of Directors

01/05/2024

Boston Pharmaceuticals Presents Data at NASH-TAG 2024 Demonstrating Low Immunogenicity Over Time With Long-acting FGF21 Analogue, BOS-580, for MASH

2023

12/19/2023

Boston Pharmaceuticals Appoints Juan Carlos Lopez-Talavera, MD, PhD, as Acting Chief Medical Officer as MASH Asset BOS-580 Accelerates in Phase 2 Clinical Program

11/10/2023

Boston Pharmaceuticals Announces Positive Phase 2a Data Supporting Once-monthly Dosing With Investigational BOS-580 in NASH and Treatment Effects in Diabetic Subgroups at AASLD The Liver Meeting^® 2023

11/7/2023

Boston Pharmaceuticals to Present New Phase 2a Data from Investigational BOS-580 NASH Program at AASLD The Liver Meeting^® 2023

06/21/2023

Boston Pharmaceuticals Announces Positive Phase 2a Results from Monthly and Bi-weekly Dosing with Investigational BOS-580 NASH Program at EASL 2023

05/18/2023

Boston Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting New Phase 2 Clinical Data from BOS-580 NASH Program at EASL 2023

2022

05/10/2022

Boston Pharmaceuticals Appoints Dr. Sophie Kornowski as Chair of its Board of Directors and Acting Chief Executive

2021

10/4/2021

Boston Pharmaceuticals Doses First Patient in Phase 2a Clinical Trial of BOS-580 for NASH

4/26/2021

Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific

3/18/2021

Boston Pharmaceuticals Enters into Unique Multi-Year Out-License and Option Agreement with GSK for the Advancement of Multiple Pre-Phase 2 Programs

2020

9/1/2020

Boston Pharmaceuticals Licenses NASH Development Candidate from Novartis

4/14/2020

Boston Pharmaceuticals Named One of the 2020 Best Workplaces in Health Care & Biopharma by Great Place to Work^® and Fortune